Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children-Reference-Cited by-同舟云学术

Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children

Published:2018-08-14 Issue:3 Volume:54 Page:448-457
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Philippe Michaël,Neely Michael,Rushing Teresa,Bertrand Yves,Bleyzac Nathalie,Goutelle Sylvain

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0281-7.pdf

Reference46 articles.

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–53.

2. Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol. 2001;114:944–50.

3. Cohen A, Békássy AN, Gaiero A, Faraci M, Zecca S, Tichelli A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008;41:S43–48.

4. Faraci M, Békássy AN, De Fazio V, Tichelli A, Dini G. EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008;41:S49–57.

5. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:167–73.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Risk Factors for Sinusoidal Obstruction Syndrome After Hematopoietic Stem Cell Transplantation in Children and Young Adults: A Systematic Review and Meta‐Analysis;Clinical Transplantation;2024-09

3. Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell Transplantation;Therapeutic Drug Monitoring;2024-05-14

4. Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience;Bone Marrow Transplantation;2024-04-09

5. Optimal Once-Daily Busulfan Administration in Pediatric Patients: A Simulation-Based Investigation of Intravenous Infusion Times;Drug Design, Development and Therapy;2024-03